LTR Pharma's Nasal Spray Treatment for Erectile Dysfunction Obtains Positive Early Results in Trial; Shares Surge 33%

LTR Pharma (ASX:LTP) received positive initial results from its clinical study of SPONTAN nasal spray treatment for erectile dysfunction, according to a Friday filing with the Australian Securities Ex

MT NewswiresJun 6 23:21 ET

LTR Pharma Requests for Voluntary Suspension Pending Clinical Study Results

LTR Pharma (ASX:LTP) requested for the suspension of its securities from quotation pending an announcement regarding the results of a primary and secondary clinical study. The voluntary suspension wil

MT NewswiresJun 6 01:52 ET

LTR Pharma Concludes Final Dose in SPONTAN Study

LTR Pharma (ASX:LTP) has completed administering the final dose to all patients recruited for its bioequivalence study of SPONTAN nasal spray, according to a Monday filing on the Australian bourse. Th

MT NewswiresMar 24 20:03 ET

LTR Pharma Doses First SPONTAN Patients

LTR Pharma (ASX:LTP) has dosed its first patients in its SPONTAN nasal spray study, according to an Australian bourse filing on Tuesday. The study will evaluate the relative bioavailability of SPONTAN

MT NewswiresMar 18 18:43 ET

LTR Pharma Launches Patient Recruitment for Erectile Dysfunction Drug Clinical Study

LTR Pharma (ASX:LTP) said Monday that it began patient recruitment for the clinical study of SPONTAN, a fast-acting, on-demand nasal spray treatment for erectile dysfunction. The research will take pl

MT NewswiresFeb 18 19:37 ET

LTR Pharma Receives Manufacturing Validation for SPONTAN Bioequivalence Study; Shares Down 3%

LTR Pharma (ASX:LTP) achieved manufacturing validation for the upcoming bioequivalence clinical study for its lead product SPONTAN, a nasal spray treatment for erectile dysfunction. The company has te

MT NewswiresFeb 5 19:41 ET